Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Olivier René und 21 weiteren Autor:innen. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Chagas Disease, Trypanocidal Agents, Triazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Innovation in 3Rs.
Abstract (Originalsprache)
Chagas Disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi, affecting millions worldwide. Current treatments suffer from variable efficacy, long duration, and safety concerns, highlighting the need for better therapies. A phenotypic screening of the Novartis compound library against Trypanosoma brucei identified cyanotriazole (CT) compounds with rapid sterilizing activity across kinetoplastids via selective inhibition of parasite topoisomerase II. First-generation CTs had safety liabilities, including lymphopenia and neutrophilia due to sphingolipid pathway modulation. Medicinal chemistry optimization led to a tailored aminopyrrolidine core structure for Chagas Disease, improving ADME properties and reducing off-target effects. IID432 showed potent activity against T. cruzi (EC50 = 8 nM) and achieved a relapse-free cure in a chronic mouse model of infection with shorter treatment duration. These findings support IID432 as a promising fast-acting, curative therapy for T. cruzi infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Olivier René, Lei Zhang, Scott A Hollingsworth, Dennis C Koester, Pearly S Ng, Srinivasa P S Rao
Förderung
- Wellcome Trust
- Innovation in 3Rs
Zitieren
APA
René, O., Saldivia, M., Dauphinais, M., Zhang, L., Hollingsworth, S. A., Jiricek, J., Koester, D. C., Miller, S. L., Williams, S. L., Ng, P. S., Patra, D., Jumani, R. S., Baxley, G. M., Osborne, C. S., Chen, Y. B., Chen, Y. L., Cheung, H., Lakshminarayana, S. B., Galarneau, J. R., …, & Rao, S. P. S. (2026). Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02459
Vancouver
René O, Saldivia M, Dauphinais M, Zhang L, Hollingsworth SA, Jiricek J, et al. Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02459
BibTeX
@article{Ren2026,
author = {René, Olivier and Saldivia, Manuel and Dauphinais, Maxime and Zhang, Lei and Hollingsworth, Scott A and Jiricek, Jan and Koester, Dennis C and Miller, Sarah L and Williams, Sarah L and Ng, Pearly S and Patra, Debjani and Jumani, Rajiv S and Baxley, Grace M and Osborne, Colin S and Chen, Ying-Bo and Chen, Yen-Liang and Cheung, Harry and Lakshminarayana, Suresh B and Galarneau, Jean-René and Diagana, Thierry T and Sarko, Christopher and Rao, Srinivasa P S},
title = {Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection Model},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02459}
}
EUVIMED